Comprehensive Molecular Profiling of Circulating Solid Tumor DNA for the Intended Use as a Broad Molecular Profiling Tool to Aid Treatment Selection

This report reviews clinical study abstracts and clinical practice guidelines addressing comprehensive molecular profiling (CMP) of circulating solid tumor DNA as a broad molecular profiling tool to aid in decision making regarding biomarker-matched treatment selection (including U.S. Food and Drug Administration [FDA]-approved or off-label use). This report will focus solely on free ctDNA detected in plasma separated from whole blood samples.

If you have a Hayes login, click here to view the full report on the Knowledge Center.